{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:44:06Z","timestamp":1790401446711,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001729","name":"Swedish Foundation for Strategic Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"crossref"}]},{"name":"KTH\/SLL"},{"name":"Swedish Infrastructure Committee","award":["SNIC2018-3-3"],"award-info":[{"award-number":["SNIC2018-3-3"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["05817, 02695, 06086"],"award-info":[{"award-number":["05817, 02695, 06086"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Regional Agreement on Medical Training and Clinical Research (ALF) for Stockholm County Council"},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sigurd and Elsa Goljes Memorial"},{"DOI":"10.13039\/100010822","name":"Axel Linders Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010822","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gun and Bertil Stohne Foundation"},{"name":"KI Funds"},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swedish Alzheimer\u2019s Foundation"},{"name":"Dementia Foundation"},{"name":"EU FW7 large-scale integrating project INMiND"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00259-019-04305-8","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T09:00:36Z","timestamp":1553677236000},"page":"1369-1382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging"],"prefix":"10.1007","volume":"46","author":[{"given":"N. Arul","family":"Murugan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Chiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rodriguez-Vieitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"\u00c5gren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Nordberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"4305_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362\u201381. \n                    https:\/\/doi.org\/10.1097\/NEN.0b013e31825018f7\n                    \n                  .","journal-title":"J Neuropathol Exp Neurol"},{"key":"4305_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-015-0220-4","volume":"3","author":"L Lemoine","year":"2015","unstructured":"Lemoine L, Saint-Aubert L, Marutle A, Antoni G, Eriksson JP, Ghetti B, et al. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun. 2015;3:40. \n                    https:\/\/doi.org\/10.1186\/s40478-015-0220-4\n                    \n                  .","journal-title":"Acta Neuropathol Commun."},{"key":"4305_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0325-z","volume":"9","author":"L Lemoine","year":"2017","unstructured":"Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017;9:96. \n                    https:\/\/doi.org\/10.1186\/s13195-017-0325-z\n                    \n                  .","journal-title":"Alzheimers Res Ther"},{"key":"4305_CR4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","volume":"79","author":"M Maruyama","year":"2013","unstructured":"Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094\u2013108. \n                    https:\/\/doi.org\/10.1016\/j.neuron.2013.07.037\n                    \n                  .","journal-title":"Neuron"},{"key":"4305_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","volume":"9","author":"CF Xia","year":"2013","unstructured":"Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. 2013;9:666\u201376. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2012.11.008\n                    \n                  .","journal-title":"Alzheimer\u2019s Dementia"},{"key":"4305_CR6","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1007\/s00259-016-3363-z","volume":"43","author":"K Chiotis","year":"2016","unstructured":"Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M, et al. Imaging in-vivo tau pathology in Alzheimer\u2019s disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging. 2016;43:1686\u201399. \n                    https:\/\/doi.org\/10.1007\/s00259-016-3363-z\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4305_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00401-016-1618-1","volume":"132","author":"KA Josephs","year":"2016","unstructured":"Josephs KA, Whitwell JL, Tacik P, Duffy JR, Senjem ML, Tosakulwong N, et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:931\u20133. \n                    https:\/\/doi.org\/10.1007\/s00401-016-1618-1\n                    \n                  .","journal-title":"Acta Neuropathol"},{"key":"4305_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ana.25060","volume":"82","author":"DR Schonhaut","year":"2017","unstructured":"Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD Sr, et al. (18) F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol. 2017;82:622\u201334. \n                    https:\/\/doi.org\/10.1002\/ana.25060\n                    \n                  .","journal-title":"Ann Neurol"},{"key":"4305_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110\u20139. \n                    https:\/\/doi.org\/10.1002\/ana.24546\n                    \n                  .","journal-title":"Ann Neurol"},{"key":"4305_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/brain\/aww340","volume":"140","author":"L Passamonti","year":"2017","unstructured":"Passamonti L, Vazquez Rodriguez P, Hong YT, Allinson KS, Williamson D, Borchert RJ, et al. 18F-AV-1451 positron emission tomography in Alzheimer\u2019s disease and progressive supranuclear palsy. Brain. 2017;140:781\u201391. \n                    https:\/\/doi.org\/10.1093\/brain\/aww340\n                    \n                  .","journal-title":"Brain"},{"key":"4305_CR11","doi-asserted-by":"publisher","unstructured":"Chiotis K, Stenkrona P, Almkvist O, Stepanov V, Ferreira D, Arakawa R, et al. Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain. Eur J Nucl Med Mol Imaging. 2018. \n                    https:\/\/doi.org\/10.1007\/s00259-018-4012-5\n                    \n                  .","DOI":"10.1007\/s00259-018-4012-5"},{"key":"4305_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0253-y","volume":"9","author":"KP Ng","year":"2017","unstructured":"Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9:25. \n                    https:\/\/doi.org\/10.1186\/s13195-017-0253-y\n                    \n                  .","journal-title":"Alzheimers Res Ther"},{"key":"4305_CR13","doi-asserted-by":"publisher","unstructured":"Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, et al. Correlations of (18)F-THK5351 PET with post-mortem burden of tau and astrogliosis in Alzheimer\u2019s disease. J Nucl Med. 2017;59(4):671-674. \n                    https:\/\/doi.org\/10.2967\/jnumed.117.197426\n                    \n                  . Society of Nuclear Medicine.","DOI":"10.2967\/jnumed.117.197426"},{"key":"4305_CR14","doi-asserted-by":"publisher","unstructured":"Vermeiren C, Motte P, Viot D, Mairet-Coello G, Courade JP, Citron M, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018;33(2):273-281.\n                    https:\/\/doi.org\/10.1002\/mds.27271\n                    \n                  .","DOI":"10.1002\/mds.27271"},{"key":"4305_CR15","doi-asserted-by":"publisher","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand [(18)F]MK-6240 in humans from Alzheimer\u2019s disease dementia to young controls. J Nucl Med. 2019;60(1):93-99. \n                    https:\/\/doi.org\/10.2967\/jnumed.118.209650\n                    \n                  . Society of Nuclear Medicine.","DOI":"10.2967\/jnumed.118.209650"},{"key":"4305_CR16","doi-asserted-by":"publisher","unstructured":"Wong DF, Comley R, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, et al. First in-human PET study of 3 novel tau radiopharmaceuticals: [(11)C]RO6924963, [(11)C]RO6931643, and [(18)F]RO6958948. J Nucl Med. 2018;59(12):1869-1876. \n                    https:\/\/doi.org\/10.2967\/jnumed.118.209916\n                    \n                  . Society of Nuclear Medicine","DOI":"10.2967\/jnumed.118.209916"},{"key":"4305_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0162-3","volume":"12","author":"L Saint-Aubert","year":"2017","unstructured":"Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12:19. \n                    https:\/\/doi.org\/10.1186\/s13024-017-0162-3\n                    \n                  .","journal-title":"Mol Neurodegener"},{"key":"4305_CR18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2165\/11596310-000000000-00000","volume":"25","author":"AH Schapira","year":"2011","unstructured":"Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson\u2019s disease: a review of symptomatic and potential disease-modifying effects. CNS drugs. 2011;25:1061\u201371. \n                    https:\/\/doi.org\/10.2165\/11596310-000000000-00000\n                    \n                  .","journal-title":"CNS drugs"},{"key":"4305_CR19","volume-title":"Gaussian 09, revision A.02","author":"MJ Frisch","year":"2009","unstructured":"Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al. Gaussian 09, revision A.02. Wallingford: Gaussian, Inc; 2009."},{"key":"4305_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nsb732","volume":"9","author":"C Binda","year":"2002","unstructured":"Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol. 2002;9:22\u20136. \n                    https:\/\/doi.org\/10.1038\/nsb732\n                    \n                  .","journal-title":"Nat Struct Biol"},{"key":"4305_CR21","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785\u201391. \n                    https:\/\/doi.org\/10.1002\/jcc.21256\n                    \n                  .","journal-title":"J Comput Chem"},{"key":"4305_CR22","doi-asserted-by":"publisher","first-page":"9750","DOI":"10.1073\/pnas.1633804100","volume":"100","author":"C Binda","year":"2003","unstructured":"Binda C, Li M, Hubalek F, Restelli N, Edmondson DE, Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci USA. 2003;100:9750\u20135. \n                    https:\/\/doi.org\/10.1073\/pnas.1633804100\n                    \n                  .","journal-title":"Proc Natl Acad Sci USA"},{"key":"4305_CR23","volume-title":"AMBER 14","author":"DA Case","year":"2014","unstructured":"Case DA, Babin V, Berryman JT, Betz RM, Cai Q, Cerutti DS, et al. AMBER 14. San Francisco: University of California; 2014."},{"key":"4305_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/jcc.21372","volume":"31","author":"G Rastelli","year":"2010","unstructured":"Rastelli G, Del Rio A, Degliesposti G, Sgobba M. Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem. 2010;31:797\u2013810. \n                    https:\/\/doi.org\/10.1002\/jcc.21372\n                    \n                  .","journal-title":"J Comput Chem"},{"key":"4305_CR25","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller 3rd","year":"2012","unstructured":"Miller BR 3rd, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA.Py: an efficient program for end-state free energy calculations. J Chem Theory Comput. 2012;8:3314\u201321. \n                    https:\/\/doi.org\/10.1021\/ct300418h\n                    \n                  .","journal-title":"J Chem Theory Comput"},{"key":"4305_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/jcbfm.2013.19","volume":"33","author":"J Tong","year":"2013","unstructured":"Tong J, Meyer JH, Furukawa Y, Boileau I, Chang LJ, Wilson AA, et al. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab. 2013;33:863\u201371. \n                    https:\/\/doi.org\/10.1038\/jcbfm.2013.19\n                    \n                  .","journal-title":"J Cereb Blood Flow Metab."},{"key":"4305_CR27","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/brain\/awv404","volume":"139","author":"E Rodriguez-Vieitez","year":"2016","unstructured":"Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Scholl M, et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer\u2019s disease. Brain. 2016;139:922\u201336. \n                    https:\/\/doi.org\/10.1093\/brain\/awv404\n                    \n                  .","journal-title":"Brain."},{"key":"4305_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology."},{"key":"4305_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303\u20138.","journal-title":"Arch Neurol"},{"key":"4305_CR30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0\n                    \n                  .","journal-title":"Lancet Neurol"},{"key":"4305_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2967\/jnumed.110.087031","volume":"53","author":"SF Carter","year":"2012","unstructured":"Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53:37\u201346. \n                    https:\/\/doi.org\/10.2967\/jnumed.110.087031\n                    \n                  . Society of Nuclear Medicine.","journal-title":"J Nucl Med."},{"key":"4305_CR32","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1021\/jm070677y","volume":"50","author":"C Binda","year":"2007","unstructured":"Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007;50:5848\u201352. \n                    https:\/\/doi.org\/10.1021\/jm070677y\n                    \n                  .","journal-title":"J Med Chem"},{"key":"4305_CR33","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1212\/WNL.67.7_suppl_2.S18","volume":"67","author":"C Caccia","year":"2006","unstructured":"Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67:S18\u201323.","journal-title":"Neurology"},{"key":"4305_CR34","doi-asserted-by":"crossref","unstructured":"Zeng Z, Miller PJ, Connolly BM, O\u2019Malley SS, Lohith T, Bennacef I, et al. In vitro binding studies to evaluate the NFT-specificity of [3H]MK-6240 and [3H]AV-1451 binding in subcortical regions of the human AD brain. Alzheimer\u2019s Dementia. 2017: IC-P-207.","DOI":"10.1016\/j.jalz.2017.06.2583"},{"key":"4305_CR35","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1111\/j.1742-4658.2011.08386.x","volume":"278","author":"EM Milczek","year":"2011","unstructured":"Milczek EM, Binda C, Rovida S, Mattevi A, Edmondson DE. The \u2018gating\u2019 residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. FEBS J. 2011;278:4860\u20139. \n                    https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08386.x\n                    \n                  .","journal-title":"FEBS J"},{"key":"4305_CR36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2967\/jnumed.116.185199","volume":"58","author":"L Declercq","year":"2017","unstructured":"Declercq L, Rombouts F, Koole M, Fierens K, Marien J, Langlois X, et al. Preclinical evaluation of (18)F-JNJ64349311, a novel PET tracer for tau imaging. J Nucl Med. 2017;58:975\u201381. \n                    https:\/\/doi.org\/10.2967\/jnumed.116.185199\n                    \n                  . Society of Nuclear Medicine.","journal-title":"J Nucl Med."},{"key":"4305_CR37","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57:1599\u2013606. \n                    https:\/\/doi.org\/10.2967\/jnumed.115.171678\n                    \n                  . Society of Nuclear Medicine.","journal-title":"J Nucl Med."},{"key":"4305_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/WCO.0000000000000502","volume":"30","author":"T Lebouvier","year":"2017","unstructured":"Lebouvier T, Pasquier F, Buee L. Update on tauopathies. Curr Opin Neurol. 2017;30:589\u201398. \n                    https:\/\/doi.org\/10.1097\/WCO.0000000000000502\n                    \n                  .","journal-title":"Curr Opin Neurol"},{"key":"4305_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.dadm.2018.01.007","volume":"10","author":"L Lemoine","year":"2018","unstructured":"Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimers Dement. 2018;10:232\u20136. \n                    https:\/\/doi.org\/10.1016\/j.dadm.2018.01.007\n                    \n                  .","journal-title":"Alzheimers Dement"},{"key":"4305_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0556-7","volume":"6","author":"A Ishiki","year":"2018","unstructured":"Ishiki A, Harada R, Kai H, Sato N, Totsune T, Tomita N, et al. Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol. 2018;6:53. \n                    https:\/\/doi.org\/10.1186\/s40478-018-0556-7\n                    \n                  .","journal-title":"Acta Neuropathol."},{"key":"4305_CR41","doi-asserted-by":"publisher","unstructured":"Hansen AK, Brooks DJ, Borghammer P. MAO-B inhibitors do not block in vivo Flortaucipir([(18)F]-AV-1451) binding. Mol Imaging Biol. 2017;20(3):356\u2013360. \n                    https:\/\/doi.org\/10.1007\/s11307-017-1143-1\n                    \n                  .","DOI":"10.1007\/s11307-017-1143-1"},{"key":"4305_CR42","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/j.1749-6632.1963.tb13336.x","volume":"107","author":"GL Gessa","year":"1963","unstructured":"Gessa GL, Cuenca E, Costa E. On the mechanism of hypotensive effects of MAO inhibitors. Ann NY Acad Sci. 1963;107:935\u201344.","journal-title":"Ann NY Acad Sci"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04305-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04305-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04305-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:16:05Z","timestamp":1585181765000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04305-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4305"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04305-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"12 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent to participate in the study, which was conducted according to the Declaration of Helsinki and subsequent revisions. Ethical approval was obtained from the regional Human Ethics Committee of Stockholm and the Faculty of Medicine and Radiation Hazard Ethics Committee of Uppsala University Hospital, Sweden.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}